Skip to main content

False Positives in the Early Stages of Drug Discovery

Buy Article:

$63.00 plus tax (Refund Policy)

Abstract:

High-throughput screening (HTS) is one of the most powerful approaches available for identifying new lead compounds for the growing catalogue of validated drug targets. However, just as virtual and experimental HTS have accelerated lead identification and changed drug discovery, they have also introduced a large number of peculiar molecules. Some of these have turned out to be interesting for further optimization, others to be dead ends when attempts are made to optimize their activity, typically after a great deal of time and resources have been devoted. Such false positive hits are still one of the key problems in the field of HTS and in the early stages of drug discovery in general. Many studies have been devoted to understanding the origins of false-positives, and the findings have been incorporated in filters and methods that can predict and eliminate problematic molecules from further consideration. This paper will focus on the structural classes and known mechanisms of nonleadlike false positives, together with experimental and computational methods for identifying such compounds.





Keywords: 2-amino-3-carbonyl tiophenes; 2-hydroxyphenylhydrazones; ALARM NMR; Acylhydrazides; Azoalkanals; CAC; CHAPS; CLND; Chymotrypsin; Clioquinol; Delavirdine; Enzyme Concentration; Epoxides; Glyburide; HTS; Hydroxyphenilhydrazones; Incubation Effect; Light Scattering; NMR; Nitroalkanes; Oxaprozin; PAINS; Perhaloketones; Plasmon Resonance; SRR (structure-reactivity relationship); Shoichet; Sulfonates; Thioepoxides; WaterLOGSY spectrum; aggregate-based promiscuous inhibitors; allopurinol; angiogenin; b-lactamase; baseline enzyme; chicken DHFR; cysteine proteases; dihydrofolate; drug discovery; hydrogen-deuterium; indiscriminate; mechanism of false-positive inhibition; metalloproteinase; methods for detecting false positives; microsecond; misinformed; more sophisticated; nicardipine; nonleadlike; omeprazole; optical biosensor surface; perplexing; photoactive dyes; prioritization; promiscuous inhibitors; pronounced capillarity; reactive compounds; red-horseradish; stoichiometry; sulfhydryl group; tetraiodophenolphthalein; thiol-reactive

Document Type: Research Article

DOI: http://dx.doi.org/10.2174/092986710793348545

Publication date: December 1, 2010

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
ben/cmc/2010/00000017/00000034/art00006
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more